Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 14,130 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Mitochondrial Myopathies, Mitochondrial Pathology, Mitochondrial DNA Mutation, Mitochondrial Diseases, Mitochondrial DNA Deletion, Mitochondrial DNA Depletion, Mitochondrial Metabolism Defect, Mitochondrial Complex I Deficiency
Interventions: Elamipretide, Placebo; Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 9
States / cities: San Diego, California • Atlanta, Georgia • Boston, Massachusetts + 6 more

Conditions: Urothelial Carcinoma, Bladder Cancer
Interventions: Atezolizumab, Enfortumab Vedotin, Niraparib, Magrolimab (Hu5F9-G4), Tiragolumab, Sacituzumab Govitecan, Tocilizumab, Cisplatin, Gemcitabine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 10
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 6 more

Conditions: Contraception
Interventions: AG200-15, Levora; Drug
Lead sponsor: Agile Therapeutics; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 407 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 21
States / cities: Mobile, Alabama • Green Valley, Arizona • Tucson, Arizona + 16 more

Conditions: Becker Muscular Dystrophy
Interventions: Sevasemten 10 mg, Sevasemten 5 mg, Sevasemten 12.5 mg, Placebo; Drug
Lead sponsor: Edgewise Therapeutics, Inc.; Industry
Eligibility: 12 Years to 50 Years · Male only
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 26
States / cities: Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 23 more

Conditions: Alopecia Areata
Interventions: CTP-543 matching placebo, CTP-543; Drug
Lead sponsor: Concert Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 517 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 25
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Los Angeles, California + 19 more

Conditions: COVID, ARDS
Interventions: PLX-PAD, Placebo; Biological
Lead sponsor: Pluristem Ltd.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 13
States / cities: Irvine, California • Los Angeles, California • Sacramento, California + 8 more

Conditions: Cocaine Use Disorder
Interventions: EMB-001, EMB-001 Placebo; Drug
Lead sponsor: Embera NeuroTherapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 4
States / cities: San Diego, California • Miami, Florida • Philadelphia, Pennsylvania + 1 more

Conditions: EPP, XLP
Interventions: Placebo, MT-7117 Low Dose, MT-7117 High Dose; Drug
Lead sponsor: Tanabe Pharma America, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 10
States / cities: Huntington Beach, California • Miami, Florida • Brighton, Massachusetts + 7 more

Conditions: Sex, Unprotected Sex, Contraception, Alcohol Use, Drug Use, Pregnancy
Interventions: Respecting the Circle of Life (RCL), Control Program; Behavioral · Other
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 11 Years and older
Enrollment: 1,072 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Whiteriver, Arizona

Conditions: Partial Epilepsy
Interventions: 800 mg QD Eslicarbazepine acetate, 1200 mg QD Eslicarbazepine acetate, Placebo; Drug
Lead sponsor: Bial - Portela C S.A.; Industry
Eligibility: 16 Years and older
Enrollment: 653 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 106
States / cities: Mobile, Alabama • Northport, Alabama • Phoenix, Arizona + 82 more

Conditions: Malaria
Interventions: VRC-MALMAB0114-00-AB, Plasmodium falciparum (P. falciparum) sporozoite challenge; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Parkinson's Disease
Interventions: FB-101, Placebo; Drug
Lead sponsor: 1ST Biotherapeutics, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV-1-infection
Interventions: Oral Lenacapavir, F/TAF, Subcutaneous Lenacapavir, TAF, BIC, B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 49
States / cities: Phoenix, Arizona • Los Angeles, California • Palm Springs, California + 40 more

Conditions: Spinal Fractures, Osteoporosis
Interventions: Percutaneous vertebroplasty, Sham vertebroplasty; Device · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 50 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: COVID-19
Interventions: Remdesivir, RDV Placebo, Standard of Care; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 12 Years and older
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 41
States / cities: Birmingham, Alabama • Mobile, Alabama • Eureka, California + 33 more

Conditions: Non Infectious Uveitis
Interventions: DE-109 Intravitreal Injections, Sham Procedure, DE-109 Intravitreal Injections (Open Label); Drug · Other
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 38
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 32 more

Conditions: Muscular Dystrophy, Duchenne, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Disease, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn
Interventions: Ataluren, PLACEBO; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 5 Years and older · Male only
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 22
States / cities: Phoenix, Arizona • Los Angeles, California • Oakland, California + 19 more

Conditions: Lennox-Gastaut Syndrome
Interventions: Rufinamide, Any other approved Antiepileptic Drug; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 1 Year to 3 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 22
States / cities: San Diego, California • Aurora, Colorado • Washington D.C., District of Columbia + 19 more

Conditions: Normal Healthy
Interventions: PF-05221304, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Atopic Dermatitis
Interventions: Ruxolitinib cream, Vehicle cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 618 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 35
States / cities: Birmingham, Alabama • Fremont, California • Huntington Beach, California + 31 more

Conditions: Critically Ill, Respiratory Failure
Interventions: Inspiratory Muscle Trainer; Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 90 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Atherosclerosis, Cardiovascular Disease
Interventions: GW856553; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Restrictive Burn Scars of Joint Area
Interventions: Autologous Human Fibroblasts (Isolagen TherapyTM), Placebo; Biological
Lead sponsor: Castle Creek Biosciences, LLC.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 3
States / cities: Boston, Massachusetts • East Meadow, New York • Galveston, Texas

Conditions: Exudative Age-related Macular Degeneration
Interventions: 4.0 mg iSONEP, 0.5 mg iSONEP, 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea, sham injection; Drug
Lead sponsor: Lpath, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 44
States / cities: Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more

Search by objective public record fields.

Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Transdermal Contraceptive Delivery System (TCDS), Also Known as AG200-15 Patch Arm

Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)

Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19

A Study to Evaluate EMB 001 in Subjects With Cocaine Use Disorder

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria

Evaluation of Respecting the Circle of Life on Pregnancy Prevention Outcomes Among American Indian Adolescents

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures

Trial to Evaluate L9LS in Healthy Adults

Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV

Vertebroplasty for the Treatment of Fractures Due to Osteoporosis

Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)

LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye

Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy

Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs

Single Dose, Repeated Dose, and Conditional Food Effect Study of PF-05221304 in Healthy Subjects

TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

A Randomized, Controlled Trial of Inspiratory Muscle Training (IMT)in the ICU and CCU

A Study Investigating Blood Concentrations Of Rosuvastatin When Co-administered With GW856553 In Healthy Men

Pilot Safety and Efficacy Study of Isolagen Therapy in Treatment of Restrictive Burn Scars

Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD